{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:16:11Z","timestamp":1791249371495,"version":"4.1.0"},"reference-count":141,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2015 - ID. 17585"],"award-info":[{"award-number":["IG 2015 - ID. 17585"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","award":["Post-Doctoral Fellowship 2018"],"award-info":[{"award-number":["Post-Doctoral Fellowship 2018"]}],"id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Italian Ministry of Health","award":["Ricerca Corrente"],"award-info":[{"award-number":["Ricerca Corrente"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cutaneous melanoma represents the most aggressive form of skin cancer, whereas vitiligo is an autoimmune disorder that leads to progressive destruction of skin melanocytes. However, vitiligo has been associated with cutaneous melanoma since the 1970s. Most of the antigens recognized by the immune system are expressed by both melanoma cells and normal melanocytes, explaining why the autoimmune response against melanocytes that led to vitiligo could be also present in melanoma patients. Leukoderma has been also observed as a side effect of melanoma immunotherapy and has always been associated with a favorable prognosis. In this review, we discuss several characteristics of the immune system responses shared by melanoma and vitiligo patients, as well as the significance of occurrence of leukoderma during immunotherapy, with special attention to check-point inhibitors.<\/jats:p>","DOI":"10.3390\/ijms20225731","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T11:25:56Z","timestamp":1573817156000},"page":"5731","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Melanoma and Vitiligo: In Good Company"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5991-8914","authenticated-orcid":false,"given":"Cristina Maria","family":"Failla","sequence":"first","affiliation":[{"name":"Experimental Immunology Laboratory, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3350-1210","authenticated-orcid":false,"given":"Maria Luigia","family":"Carbone","sequence":"additional","affiliation":[{"name":"Experimental Immunology Laboratory, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Fortes","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Pagnanelli","sequence":"additional","affiliation":[{"name":"1st Dermatology Division, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"D\u2019Atri","sequence":"additional","affiliation":[{"name":"Molecular Oncology Laboratory, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"E11101","DOI":"10.1073\/pnas.1807256115","article-title":"Criticality in tumor evolution and clinical outcome","volume":"115","author":"Persi","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","first-page":"2535","article-title":"Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma","volume":"63","author":"Mortarini","year":"2003","journal-title":"Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/9525","article-title":"Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients","volume":"5","author":"Lee","year":"1999","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1529-8019.2005.05005.x","article-title":"Management of nevi in transplant patients","volume":"18","author":"Baron","year":"2005","journal-title":"Dermatol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/CMR.0b013e328322fc20","article-title":"Immunosuppression and melanocyte proliferation","volume":"19","author":"Zattra","year":"2009","journal-title":"Melanoma Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","article-title":"Deciphering and reversing tumor immune suppression","volume":"39","author":"Motz","year":"2013","journal-title":"Immunity"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.canlet.2019.10.013","article-title":"Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion","volume":"468","author":"Jiang","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/imm.12917","article-title":"Hypoxia and acidosis: Immune suppressors and therapeutic targets","volume":"154","author":"Damgaci","year":"2018","journal-title":"Immunology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000253915","article-title":"Malignant melanoma and vitiligo","volume":"139","author":"Balabanov","year":"1969","journal-title":"Dermatologica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1046\/j.1523-1747.2001.01408.x","article-title":"Specific cytotoxic T lymphocyte responses against Melan-A\/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex\/peptide tetramers: The role of cellular immunity in the etiopathogenesis of vitiligo","volume":"117","author":"Palermo","year":"2001","journal-title":"J. Invest. Dermatol"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","article-title":"Vitiligo Working Group, New discoveries in the pathogenesis and classification of vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/pcmr.12294","article-title":"The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo","volume":"27","author":"Teulings","year":"2014","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2302\/kjm.50.86","article-title":"Melanoma antigens and their recognition by T. cells","volume":"50","author":"Parmiani","year":"2001","journal-title":"Keio J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0167-5699(97)84664-6","article-title":"Cancer vaccines based on the identification of genes encoding cancer regression antigens","volume":"18","author":"Rosenberg","year":"1997","journal-title":"Immunol. Today"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/(SICI)1097-0215(20000515)86:4<538::AID-IJC16>3.0.CO;2-G","article-title":"Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides","volume":"86","author":"Jager","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1084\/jem.192.11.1637","article-title":"Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell\u2013mediated vitiligo","volume":"192","author":"Yee","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40425-017-0307-5","article-title":"Improved survival and tumor control with interleukin-2 is associated with the development of immune-related adverse events: Data from the PROCLAIMSM registry","volume":"5","author":"Curti","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.clim.2016.07.006","article-title":"Metastatic melanoma and immunotherapy","volume":"172","author":"Herzberg","year":"2016","journal-title":"Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advance melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/CMR.0000000000000573","article-title":"Melanoma and autoimmunity: Spontaneous regressions as a possible model for new therapeutic approaches","volume":"29","author":"Motofei","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3389\/fimmu.2019.01198","article-title":"Autoreactive T-Lymphocytes in Inflammatory Skin Diseases","volume":"10","author":"Boehncke","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.autrev.2016.01.004","article-title":"The role of IL-17 in vitiligo: A review","volume":"15","author":"Singh","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_29","first-page":"155","article-title":"Prognostic significance of cutaneous depigmentation in Mexican patients with malignant melanoma","volume":"29","year":"1998","journal-title":"Arch. Med. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1365-4632.2004.02468.x","article-title":"Regressing cutaneous malignant melanoma and vitiligo-like depigmentation","volume":"45","author":"Arpaia","year":"2006","journal-title":"Int. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jdcr.2018.05.008","article-title":"Two reports of malignant melanoma arising within vitiligo-like depigmented patch","volume":"4","author":"Francisco","year":"2018","journal-title":"JAAD Case Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/pcmr.12161","article-title":"Melanoma-associated leukoderma-immunology in black and white?","volume":"26","author":"Naveh","year":"2013","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jaad.2018.03.063","article-title":"Acquired disorders with depigmentation: A systematic approach to vitiliginoid conditions","volume":"80","author":"Saleem","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1610-0387.2008.06755.x","article-title":"Vitiligo and melanoma-associated hypopigmentation (MAH): Shared and discriminative features","volume":"6","author":"Hartmann","year":"2008","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jaad.2016.07.060","article-title":"Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field","volume":"75","author":"Lommerts","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/archderm.1995.01690150078015","article-title":"Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells","volume":"131","author":"Cui","year":"1995","journal-title":"Arch. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1002\/1097-0142(19931015)72:8<2365::AID-CNCR2820720812>3.0.CO;2-G","article-title":"Vitiligo autoantibodies are effective against melanoma","volume":"72","author":"Fishman","year":"1993","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02737633","article-title":"The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions","volume":"16","author":"Merimsky","year":"1998","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1046\/j.1523-1747.1999.00805.x","article-title":"Accumulation of identical T cells in melanoma and vitiligo-like leukoderma","volume":"113","author":"Becker","year":"1999","journal-title":"J. Invest. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1002\/eji.200535110","article-title":"Qualitative difference between the cytotoxic T Lymphocyte responses to melanocyte antigens in melanoma and vitiligo","volume":"35","author":"Palermo","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lili, Y., Yi, W., Ji, Y., Yue, S., Weimin, S., and Ming, L. (2012). Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0037513"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/0008-5472.CAN-03-2828","article-title":"Spontaneous vitiligo in an animal model for human melanoma: Role of tumor-specific CD8+ T cells","volume":"64","author":"Lengagne","year":"2004","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/pcmr.12591","article-title":"UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model","volume":"30","author":"Wang","year":"2017","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/pcmr.12769","article-title":"Pathology of spontaneous and immunotherapy-induced tumor regression in a murine model of melanoma","volume":"32","author":"Blenman","year":"2019","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI44849","article-title":"Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma","volume":"121","author":"Byrne","year":"2011","journal-title":"J. Clin. Invest."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1111\/ijd.12843","article-title":"Halo nevus: Review of the literature and clinicopathologic findings","volume":"54","author":"Weyant","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1111\/j.1468-3083.2012.04504.x","article-title":"Association of halo\/nevus\/i and vitiligo in childhood: A retrospective observational study","volume":"27","author":"Patrizi","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jdermsci.2017.03.008","article-title":"A similar local immune and oxidative stress phenotype in vitiligo and halo nevus","volume":"87","author":"Yang","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/j.seminoncol.2016.02.031","article-title":"Cutaneous manifestations associated with melanoma","volume":"43","author":"Vyas","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/jama.1973.03220310013003","article-title":"Halo Nevi and Melanoma","volume":"225","author":"Epstein","year":"1973","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdp325","article-title":"Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: Results from a single-institution hospital-based observational cohort study","volume":"21","author":"Quaglino","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1600-0560.2006.00616.x","article-title":"Fibrosis in regressing melanoma versus nonfibrosis in halo nevus upon melanocyte disappearance: Could it be related to a different cytokine microenvironment?","volume":"34","author":"Moretti","year":"2007","journal-title":"J. Cutan. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jaad.2010.11.061","article-title":"Vitiligo: A comprehensive overview","volume":"65","author":"Alikhan","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_54","first-page":"659","article-title":"Morphological features of melanocytic tumors with depigmented halo: Review of the literature and personal results","volume":"56","author":"Nedelcu","year":"2015","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e1593806","DOI":"10.1080\/2162402X.2019.1593806","article-title":"Prognostic value of tumor-infitrating lymphocytes in melanoma: A systematic review and meta-analysis","volume":"8","author":"Fu","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1084\/jem.190.5.651","article-title":"An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanoma-specific antigen in metastatic melanomapatients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions","volume":"190","author":"Anichini","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1034\/j.1600-065X.2002.18809.x","article-title":"Immunity to cancer: Attack and escape in T lymphocyte-tumor cell interaction","volume":"188","author":"Rivoltini","year":"2002","journal-title":"Immunol. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1084\/jem.190.11.1669","article-title":"Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma","volume":"190","author":"Thurner","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"MMT20","DOI":"10.2217\/mmt-2018-0010","article-title":"Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma","volume":"6","author":"Dillman","year":"2019","journal-title":"Melanoma Manag."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1600-0749.1995.tb00775.x","article-title":"Antimelanoma antibodies in swine with spontaneously regressing melanoma","volume":"8","author":"Cui","year":"1995","journal-title":"Pigment. Cell Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1084\/jem.182.5.1609","article-title":"Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the brown locus protein","volume":"182","author":"Hara","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-07-1264","article-title":"Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor","volume":"67","author":"Zhang","year":"2007","journal-title":"Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/CMR.0000000000000518","article-title":"Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma","volume":"29","author":"Hwang","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: A systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma","volume":"145","author":"Indini","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamadermatol.2017.0581","article-title":"Pembrolizumab-Induced Extensive Panniculitis and Nevus Regression: Two Novel Cutaneous Manifestations of the Post-immunotherapy Granulomatous Reactions Spectrum","volume":"153","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/CMR.0000000000000555","article-title":"Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy","volume":"29","author":"Plaquevent","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/jamadermatol.2017.0615","article-title":"Induction of Immune Reaction in Benign Melanocytic Nevi Without Halo During Nivolumab Therapy in a Patient With Melanoma","volume":"153","author":"Nakamura","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Dimitriou, F., Mangana, J., and Dummer, R. (2019). Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy. Acta. Derm. Venereol., Epub ahead of print.","DOI":"10.2340\/00015555-3355"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055","article-title":"Hair disorders in patients with cancer","volume":"80","author":"Shapiro","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ophtha.2008.12.004","article-title":"Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma","volume":"116","author":"Yeh","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Mihailovic, N., Dyballa, J., Herz, S., Fluck, M., Alnawaiseh, M., Mert\u00e9, R.L., and Nicole, E. (2019). Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma. Ophthalmologe, 5.","DOI":"10.1007\/s00347-019-00963-z"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamadermatol.2017.1679","article-title":"Nivolumab Therapy for Treatment-Related Vitiligo in a Patient With Relapsed Metastatic Melanoma","volume":"153","author":"Nakamura","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"eaam6346","DOI":"10.1126\/sciimmunol.aam6346","article-title":"Resident memory T cells in the skin mediate durable immunity to melanoma","volume":"2","author":"Malik","year":"2017","journal-title":"Sci. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/bjd.14416","article-title":"Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo","volume":"174","author":"Wang","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1002\/cncr.32326","article-title":"To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease","volume":"125","author":"Pantuck","year":"2019","journal-title":"Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.semcancer.2017.09.004","article-title":"Emerging biomarkers for cancer immunotherapy in melanoma","volume":"52","author":"Axelrod","year":"2018","journal-title":"Sem. Cancer Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3389\/fimmu.2018.01474","article-title":"Biomarkers for clinical benefit of immune checkpoint inhibitor treatment\u2014A review from the melanoma perspective and beyond","volume":"9","author":"Hassel","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Otoshi, T., Nagano, T., Tachihara, M., and Nishimura, Y. (2019). Possible biomarkers for cancer immunotherapy. Cancer, 11.","DOI":"10.3390\/cancers11070935"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/annonc\/mdw016","article-title":"Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab","volume":"27","author":"Ferrucci","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"468","DOI":"10.5114\/ada.2017.71114","article-title":"Neutrophil to lymphocyte ratio in patients with vitiligo","volume":"34","author":"Solak","year":"2017","journal-title":"Adv. Dermatol. Allergol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/exd.13952","article-title":"Expression analysis of PD-1 and Tim-3 immune checkpoint receptors in patients with vitiligo; positive association with disease activity","volume":"28","author":"Rahimi","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","article-title":"An immune-active tumor microenvironment favors clinical response to ipilimumab","volume":"61","author":"Ji","year":"2012","journal-title":"Cancer Immunol. Immunother"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.autrev.2017.07.005","article-title":"Biomarkers of disease activity in vitiligo: A systematic review","volume":"16","author":"Speeckaert","year":"2017","journal-title":"Autoimmunity Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"819829","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/CCID.S210106","article-title":"Role of Janus kinase I and signal transduce and activator of transcription 3 in vitiligo","volume":"12","author":"Samaka","year":"2019","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1172\/JCI87324","article-title":"Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma","volume":"126","author":"Daud","year":"2016","journal-title":"J. Clin. Invest."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3389\/fimmu.2017.00386","article-title":"Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study","volume":"8","author":"Queirolo","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.det.2016.11.013","article-title":"Genetics of Vitiligo","volume":"35","author":"Spritz","year":"2017","journal-title":"Dermatol. Clin."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1034\/j.1600-0749.2001.140608.x","article-title":"\u2018VIT1\u2032, a novel gene associated with vitiligo","volume":"14","author":"Sarangarajan","year":"2001","journal-title":"Pigment. Cell Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajmg.a.32210","article-title":"Compound heterozygosity for two MSH6 mutations in a patient with early onset colorectal cancer, vitiligo and systemic lupus erythematosus","volume":"146","author":"Rahner","year":"2008","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1172\/JCI98060","article-title":"Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma","volume":"128","author":"Huber","year":"2018","journal-title":"J. Clin. Invest."},{"key":"ref_102","first-page":"742","article-title":"MicroRNA-155 is Dysregulated in the Skin of Patients with Vitiligo and Inhibits Melanogenesis-associated Genes in Melanocytes and Keratinocytes","volume":"96","author":"Tankov","year":"2016","journal-title":"Acta. Derm. Venereol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/pcmr.12086","article-title":"MicroRNA expression profiling identifies potential serum biomarkers for non-segmental vitiligo","volume":"26","author":"Shi","year":"2013","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"10079","DOI":"10.1038\/s41598-019-46529-6","article-title":"Micro RNAs upregulated in vitiligo skin play an important role in its aetiopathogenesis by altering TRP-1 expression and keratinocyte-melanocytes cross-talk","volume":"9","author":"Vaish","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758834017749748","article-title":"Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients","volume":"10","author":"Karachaliou","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_106","first-page":"e303","article-title":"MIG Th1 chemokine in vitiligo","volume":"169","author":"Elia","year":"2018","journal-title":"Clin. Ter."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1203475419833609","article-title":"The use of Janus kinase inhibitors in vitiligo: A review of the literature","volume":"23","author":"Relke","year":"2019","journal-title":"J. Cut. Med. Surg."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"26395","DOI":"10.1074\/jbc.R115.660142","article-title":"Mismatch repair","volume":"290","author":"Fishel","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3892\/ijo.2015.3119","article-title":"Deficient mismatch repair: Read all about it (Review)","volume":"47","author":"Richman","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1634\/theoncologist.2016-0046","article-title":"Mismatch repair deficiency and response to immune checkpoint blockade","volume":"21","author":"Lee","year":"2016","journal-title":"Oncologist"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/exd.12319","article-title":"Serum miRNA expression profiles change in autoimmune vitiligo in mice","volume":"23","author":"Shi","year":"2014","journal-title":"Exp. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1684\/ejd.2017.3024","article-title":"MicroRNA in skin diseases","volume":"27","author":"Ruksha","year":"2017","journal-title":"Eur. J. Dermatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: Treatment options and future prospects","volume":"101","author":"Carvajal","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/eye.2016.275","article-title":"Uveal melanoma: Relatively rare but deadly cancer","volume":"31","author":"Kaliki","year":"2017","journal-title":"Eye"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/cco.2018.01.05","article-title":"Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma","volume":"7","author":"Jindal","year":"2018","journal-title":"Chin. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Schank, T.E., and Hassel, J.C. (2019). Immunotherapies for the treatment of uveal melanoma-history and future. Cancers, 11.","DOI":"10.3390\/cancers11081048"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Zimmer, L., Vaubel, J., Mohr, P., Hauschild, A., Utikal, J.S., Simon, J., Garbe, C., Herbst, R., Enk, A., and Kampgen, E. (2015). Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0118564"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/cncr.30258","article-title":"Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies","volume":"122","author":"Algazi","year":"2016","journal-title":"Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2017.05.038","article-title":"Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1\/cytotoxic T-lymphocyte antigen-4 inhibition","volume":"82","author":"Heppt","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40425-019-0533-0","article-title":"Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors","volume":"7","author":"Rapisuwon","year":"2019","journal-title":"J. Immunother Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Fountain, E., Bassett, R.L., Cain, S., Posada, L., Gombos, D.S., Hwu, P., Bedikian, A., and Patel, S.P. (2019). Adjuvant Ipilimumab in High-Risk Uveal Melanoma. Cancers, 11.","DOI":"10.3390\/cancers11020152"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_124","first-page":"283","article-title":"Immunotherapy \u201cShock\u201d with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma","volume":"22","author":"Zarogoulidis","year":"2017","journal-title":"Respir Med. Case Rep."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jdcr.2018.08.009","article-title":"Vitiligo in a patient undergoing nivolumab treatment for non-small cell lung cancer","volume":"4","author":"Kosche","year":"2018","journal-title":"JAAD Case Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/ced.13867","article-title":"Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers","volume":"44","author":"Liu","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e13810","DOI":"10.1097\/MD.0000000000013810","article-title":"Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma","volume":"97","author":"Lolli","year":"2018","journal-title":"Medicine"},{"key":"ref_128","first-page":"CD011123","article-title":"Systemic treatments for metastatic cutaneous melanoma","volume":"2","author":"Pasquali","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jamadermatol.2015.0249","article-title":"Occurence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma","volume":"151","author":"Ohtsuka","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jamadermatol.2015.5210","article-title":"Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma","volume":"152","author":"Totonchy","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/jdv.13336","article-title":"Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma","volume":"30","author":"Kato","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2340\/00015555-2212","article-title":"Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma","volume":"96","author":"Matsumura","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"ref_133","first-page":"2324709616674316","article-title":"Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: A report of 2 patients cases","volume":"4","author":"Phadke","year":"2016","journal-title":"J. Invest. Med. High. Impact Case Rep."},{"key":"ref_134","first-page":"e254","article-title":"Anti-PD1-induced psoriasis: A study of 21 patients","volume":"31","author":"Bonigen","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.currproblcancer.2017.10.003","article-title":"Anti-PD1\/PDL1 induced psoriasis","volume":"41","author":"Voudouri","year":"2017","journal-title":"Curr. Probl. Cancer"},{"key":"ref_136","first-page":"742","article-title":"Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma","volume":"15","author":"Schmidgen","year":"2017","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cup.12735","article-title":"Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma","volume":"43","author":"Mochel","year":"2016","journal-title":"J. Cutan. Pathol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/CMR.0000000000000155","article-title":"A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab","volume":"25","author":"Carlos","year":"2015","journal-title":"Melanoma Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/CMR.0000000000000260","article-title":"Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res."},{"key":"ref_140","first-page":"224","article-title":"Nivolumab-induced Lichen Planus Pemphigoides","volume":"103","author":"Strickley","year":"2019","journal-title":"Cutis"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of nivolumab-induced Bullous Pemphigoid: Review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and reccomendations for diagnosis and management","volume":"23","author":"Lopez","year":"2018","journal-title":"Oncologist"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/22\/5731\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:34:41Z","timestamp":1760189681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/22\/5731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":141,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["ijms20225731"],"URL":"https:\/\/doi.org\/10.3390\/ijms20225731","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]}}}